Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

Authors :: Padimac investigators
Laura Clifton-Hadley
Dunnya De-Silva
Treen C. M. Morris
Nicholas Counsell
Wei Yee Chan
Elizabeth H Phillips
Neil Rabin
Roger G. Owen
Gordon Cook
Rakesh Popat
Jamie Cavenagh
Ruth M. de Tute
Matthew Streetly
Mickey Koh
Nivette Braganca
Josephine Crowe
Kwee Yong
Stephen Schey
Toyin Adedayo
Claire Roddie
Source :: British Journal of Haematology. 196
Publication Year :: 2021
Publisher :: Wiley, 2021.

Subjects :: Oncology
Very Good Partial Response
medicine.medical_specialty
Chemotherapy
business.industry
Bortezomib
medicine.medical_treatment
Hematology
medicine.disease
Autologous stem-cell transplantation
Internal medicine
medicine
In patient
Stem cell
business
Dexamethasone
Multiple myeloma
medicine.drug

Full Text Access

Tools